TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03227549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Superior Approach
Description: Total hip arthroplasty using direct superior approach

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty using direct superior or posterior approach
Study: NCT02145156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored educational materials
Description: The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
Study: NCT03227549

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Total Hip Arthroplasty using direct superior or posterior approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Approach
Description: Total Hip Arthroplasty using posterior approach
Study: NCT04392349

Intervention type: DEVICE
Group type: OTHER
Intervention: Zeiss ATLAS 9000
Description: ATLAS is a corneal topography system used as representative device for measurement of anterior corneal curvature (anterior corneal topography).
Study: NCT02396992

Intervention type: OTHER
Group type: OTHER
Intervention: Minimal-Massive Intervention
Description: The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
Study: NCT03875248

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood pressure measurement
Description: Measure optically the blood pressure through the use of a smartphone

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood pressure measurement
Description: Measure optically the blood pressure through the use of a smartphone

Intervention type: DEVICE
Group type: OTHER
Intervention: Blood pressure measurement
Description: Measure optically the blood pressure through the use of a smartphone
Study: NCT03264248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-Scale
Description: Daily bodyweight system used under legs of bed
Study: NCT02939495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapoxetine/Sildenafil 30/50 mg film coated tablet
Description: 1 tablet before sexual intercourse
Study: NCT00513734

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel dressing
Description: 3x3cm hydrogel dressing over closed eye
Study: NCT01446224

Intervention type: DRUG
Intervention: Pazopanib
Description: Patients treated with pazopanib
Study: NCT00513734

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lacrilube ointment
Description: lubricant put into eye (inferior formix)
Study: NCT04081506

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized perfusion targets
Description: Targeting +/-5mmHg of the optimal mean arterial pressure
Study: NCT02488174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PROOFcheck

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Study: NCT00280488

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview
Description: Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
Study: NCT04026191

Intervention type: DEVICE
Group type: OTHER
Intervention: OrthoVisc®-T (OVT)
Description: Sodium hyaluronate supplied as a 2 mL (15mg/mL) unit dose in a 3 mL glass syringe.
Study: NCT02973243

Intervention type: DEVICE
Intervention: Automatic RR Measurement
Description: Different newly developed respiration rate sensors are applied at the bedside during the intervention phase which send data to the IntelliVue Guardian System.
Study: NCT03237936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg/mL ciclosporin
Description: IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
Study: NCT00280488

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assessment
Description: In the assessment-only condition, patients will receive only assessment of their drinking at baseline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview
Description: Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
Study: NCT03651531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Weight based insulin will be calculated using 0.7 units/kg/day in the first trimester, 0.8 units/kg/day in the second trimester and 1 units/kg/day in the third trimester. This total insulin will then be divided into short acting insulin and intermediate acting insulin per provider discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Weight based insulin will be calculated using 0.7 units/kg/day in the first trimester, 0.8 units/kg/day in the second trimester and 1 units/kg/day in the third trimester. This total insulin will then be divided into short acting insulin and intermediate acting insulin per provider discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Will be initiated at dose of 500 mg twice daily. If glycemic control is suboptimal, the dose of metformin will be increased to 1000 mg twice a day. Metformin will be titrated prior to increases in insulin.
Study: NCT04914936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 in Part 1, Part 2, and Part 3; and on Day 1 of Period 2 in Part 1, Day 5 of Period 2 in Part 2, and Day 1 and Day 9 of Period 2 in Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 in Part 1, Part 2, and Part 3; and on Day 1 of Period 2 in Part 1, Day 5 of Period 2 in Part 2, and Day 1 and Day 9 of Period 2 in Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: Participants will receive a single oral dose of ACP-196 100 mg capsule on Day 1 of Period 1 in Part 1, Part 2, and Part 3; and on Day 1 of Period 2 in Part 1, Day 5 of Period 2 in Part 2, and Day 1 and Day 9 of Period 2 in Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Participants will receive a single oral dose of calcium carbonate 1 g tablet on Day 1 of Period 2 in Part 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants will receive multiple oral doses of omeprazole 40 mg capsules QD for 5 consecutive days in Period 2 of Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Participants will receive multiple oral doses of rifampin 600 mg capsule QD for 9 consecutive days in Period 2 of Part 3.
Study: NCT02848027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regenexx SD® procedure
Description: Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
Study: NCT02145156

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Untailored educational materials
Description: The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Survey-only
Description: Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
Study: NCT01631279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR610
Description: Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
Study: NCT02512003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fantom Scaffold
Study: NCT01889446

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium propionate
Study: NCT01955863

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: patient discharge on postoperative day 2
Description: The patient was discharge on postoperative day 2 (as was done routinely)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient discharge on postoperative day 1
Description: The patient was discharge on postoperative day 1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient discharge in the day of surgery
Description: The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
Study: NCT02268656

Intervention type: DRUG
Group type: OTHER
Intervention: propofol concentration
Description: First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method

Intervention type: DRUG
Group type: OTHER
Intervention: propofol concentration
Description: First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
Study: NCT03376282

Intervention type: OTHER
Group type: OTHER
Intervention: Hyperbaric Oxygen oxygen therapy (HBOT)
Description: 60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
Study: NCT01756742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy
Description: The respiratory physiotherapy intervention included:~* Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)~* Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conservative treatment
Description: Conservative medical treatment intervention for pleural effusion.
Study: NCT06537687

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A standardized handout on HPV and vaccine education will be given
Study: NCT03099824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-101
Description: 82 mg (1 capsule)
Study: NCT06537687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A video about HPV and vaccines on a tablet provided by a research assistant
Study: NCT03361631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow derived Mesenchymal Stem Cells
Description: Information visit (time 1) Inclusion visit (time 2) Bone marrow extraction (time 3) Treatment and culture of MSC (time 4) Intra-cavernosal injection of autologous MSC (time 5) Follow-up 1 (time 6): control / tolerance visit (andrological clinical examination, EHS and and IIEF-5), 2 weeks after injection; Follow-up 2 (time 7): 12-week evaluation of treatment response: andrological clinical examination, IIEF-5 and EHS score determination \& Pharmaco-Doppler; Follow-up 3 (time 8): 24-week evaluation of the response to treatment: andrological clinical examination, determination of IIEF-5 and EHS scores \& Pharmaco-Doppler
Study: NCT01442610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: Rasagiline tablets 1mg once daily for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1tablet once daily for 8 weeks
Study: NCT02343185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual therapy with diaphragmatic treatment
Description: Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
Study: NCT00330733

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salsalate
Description: Participants were randomized to 12-week treatment with up to 4 g/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were randomized to 12-week treatment matching the active salsalate arm.
Study: NCT02382146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone ondansetron
Description: dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone dimenhidrinate
Description: dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
Study: NCT03246880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin 0.2mg
Description: per oral for 12weeks after 2\~4weeks run-in period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2mg
Description: per oral for 12weeks after 2\~4weeks run-in period
Study: NCT01446224

Intervention type: DRUG
Intervention: Pazopanib
Description: Patients treated with pazopanib

Intervention type: DRUG
Intervention: Other anti-VEGFs
Description: Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
Study: NCT03099824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV GC4419
Description: GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV GC4419
Description: GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV GC4419
Description: GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV GC4419
Description: GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
Study: NCT01446224

Intervention type: DRUG
Intervention: Other anti-VEGFs
Description: Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib

Intervention type: DRUG
Intervention: Other anti-VEGFs
Description: Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib

Intervention type: DRUG
Intervention: Other anti-VEGFs
Description: Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
Study: NCT02838940

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood samples.
Description: At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.~Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
Study: NCT01483625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: 18mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03099824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV GC4419
Description: GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-101
Description: 164 mg (2 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-101
Description: 246 mg (3 capsules)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-111
Description: 175 mg (1 capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-112
Description: 145 mg (1 capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-119
Description: 233 mg (1 capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC4711 Oral Capsule G-125
Description: 233 mg (1 capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV GC4711
Description: GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV GC4711
Description: GC4711 will be infused IV as a single dose of 30 mg in 250 mL normal saline, totaling 251 mL, over a 60-minute period using a programmable pump.
Study: NCT01133236

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt and fluid restriction
Description: I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.~II: Control Prescription without sodium and fluid restriction.
Study: NCT03537651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEZ/IVA
Description: Fixed-dose combination tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Tablet for oral administration.
Study: NCT04619303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant
Description: Intravitreal injection of 0.7mg dexamethasone implant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injectable Product
Description: Invtravitreal injection of 1.25mg/0.05mL bevacizumab
Study: NCT04033237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Description: Cigarettes containing 0.4 mg nicotine/g tobacco
Study: NCT05527236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercise
Description: The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm), the breathing exercise group was made breathing exercises again. As soon as the virtual reality glasses and breathing exercise device were removed, VAS was applied. In order to evaluate the second and third stages of labor, the birth evaluation section of the labor observation form was filled out. Satisfaction with birth was evaluated with the ''Birth Satisfaction Scale'' within the first 4 hours after birth after the delivery was completed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The research was carried out in two stages. In the first stage, for the experimental groups at the 36th-39th weeks of pregnancy, a 10-minute breathing exercise was performed 3 times a week using virtual reality glasses and a breathing exercise device. In the second stage of the study (when the cervical dilatation was 4 cm) the virtual reality group watched a 10-minute video with virtual reality glasses. Once the virtual reality glasses were removed from experimental groups Visual Analogue Scale was applied. Birth satisfaction was evaluated with the Birth Satisfaction Scale within the first 4 hours after the delivery was completed.
Study: NCT06112717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive-Educative Nursing Care
Description: Adolescents in the intervention group were received Supportive-Educative Nursing Care based on Orem's Self Care Deficit Nursing Theory
Study: NCT01186848

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combination treatment
Description: The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1550-nm erbium-doped fractionated laser
Description: Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
Study: NCT03966794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Electrical Stimulation
Description: Participants had finished the previous clinical trial with functional neural regeneration collagen scaffold transplantation, and will receive epidural electrical stimulation of the spinal cord in this group.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Functional scaffold & Epidural Electrical Stimulation
Description: Participants with acute complete SCI or chronic complete SCI will receive functional neural regeneration scaffold transplantation and epidural electrical stimulation of the spinal cord.
Study: NCT03203356

Intervention type: DRUG
Intervention: growth hormone
Description: Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
Study: NCT00208507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 28 mm ceramic head on ceramic acetabular liner.
Description: Total hip replacement with 28 mm ceramic head on ceramic liner articulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 28 mm ceramic head on polyethylene liner
Description: Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
Study: NCT03707678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2245035
Description: GSK2245035 will be administered weekly once as a nasal spray solution with dosing strength of 10 ng per actuation. GSK2245035 will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered weekly once as a nasal spray solution. Placebo will be available as a saline formulation, preserved with benzalkonium chloride and disodium edetate in an amber glass bottle fitted with a screw-fit atomizing pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-DPI
Description: FP will be administered using Diskus inhaler with dosing strengths of 500, 250, 100, 50 µg twice daily per actuation.